Cargando…
Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma
This study aimed to reveal the prognostic role of the Hippo pathway in different histopathological subtypes of renal cell carcinoma (RCC). The TCGA‐KIRC (n = 537), TCGA‐KIRP (n = 291) and TCGA‐KICH (n = 113), which contain data about clear cell (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC),...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806300/ https://www.ncbi.nlm.nih.gov/pubmed/36478130 http://dx.doi.org/10.1111/jcmm.17632 |
_version_ | 1784862506615832576 |
---|---|
author | Duong, Nguyen Xuong Le, Minh‐Khang Kondo, Tetsuo Mitsui, Takahiko |
author_facet | Duong, Nguyen Xuong Le, Minh‐Khang Kondo, Tetsuo Mitsui, Takahiko |
author_sort | Duong, Nguyen Xuong |
collection | PubMed |
description | This study aimed to reveal the prognostic role of the Hippo pathway in different histopathological subtypes of renal cell carcinoma (RCC). The TCGA‐KIRC (n = 537), TCGA‐KIRP (n = 291) and TCGA‐KICH (n = 113), which contain data about clear cell (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC), respectively, were investigated. Gene Set Variation Analysis was used to compare the activity of many pathways within a single sample. Oncogenic pathway‐related expression differed between cases of ccRCC involving low and high Hippo pathway activity. There were two subsets of ccRCC, in which the cancer exhibited lower and higher Hippo signalling activity, respectively, compared with normal tissue. In the ccRCC cohort, lower Hippo pathway activity was associated with a higher clinical stage (p < 0.001). The Hippo pathway (HR = 0.29; 95% CI = 0.17–0.50, p < 0.001), apoptosis (HR = 6.02; 95% CI = 1.47–24.61; p = 0.013) and the p53 pathway (HR = 0.09; 95% CI = 0.02–0.36; p < 0.001) were identified as independent prognostic factors for ccRCC. The 5‐year overall survival of the ccRCC patients with low and high Hippo pathway activity were 51.9% (95% CI = 45.0–59.9) and 73.6% (95% CI = 67.8–79.9), respectively. In conclusion, the Hippo pathway plays an important role in the progression of ccRCC. Low Hippo pathway activity is associated with poor outcomes in ccRCC, indicating the tumour suppressor function of this pathway. |
format | Online Article Text |
id | pubmed-9806300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98063002023-01-04 Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma Duong, Nguyen Xuong Le, Minh‐Khang Kondo, Tetsuo Mitsui, Takahiko J Cell Mol Med Original Articles This study aimed to reveal the prognostic role of the Hippo pathway in different histopathological subtypes of renal cell carcinoma (RCC). The TCGA‐KIRC (n = 537), TCGA‐KIRP (n = 291) and TCGA‐KICH (n = 113), which contain data about clear cell (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC), respectively, were investigated. Gene Set Variation Analysis was used to compare the activity of many pathways within a single sample. Oncogenic pathway‐related expression differed between cases of ccRCC involving low and high Hippo pathway activity. There were two subsets of ccRCC, in which the cancer exhibited lower and higher Hippo signalling activity, respectively, compared with normal tissue. In the ccRCC cohort, lower Hippo pathway activity was associated with a higher clinical stage (p < 0.001). The Hippo pathway (HR = 0.29; 95% CI = 0.17–0.50, p < 0.001), apoptosis (HR = 6.02; 95% CI = 1.47–24.61; p = 0.013) and the p53 pathway (HR = 0.09; 95% CI = 0.02–0.36; p < 0.001) were identified as independent prognostic factors for ccRCC. The 5‐year overall survival of the ccRCC patients with low and high Hippo pathway activity were 51.9% (95% CI = 45.0–59.9) and 73.6% (95% CI = 67.8–79.9), respectively. In conclusion, the Hippo pathway plays an important role in the progression of ccRCC. Low Hippo pathway activity is associated with poor outcomes in ccRCC, indicating the tumour suppressor function of this pathway. John Wiley and Sons Inc. 2022-12-07 /pmc/articles/PMC9806300/ /pubmed/36478130 http://dx.doi.org/10.1111/jcmm.17632 Text en © 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Duong, Nguyen Xuong Le, Minh‐Khang Kondo, Tetsuo Mitsui, Takahiko Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma |
title | Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma |
title_full | Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma |
title_fullStr | Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma |
title_full_unstemmed | Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma |
title_short | Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma |
title_sort | heterogeneity of hippo signalling activity in different histopathologic subtypes of renal cell carcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806300/ https://www.ncbi.nlm.nih.gov/pubmed/36478130 http://dx.doi.org/10.1111/jcmm.17632 |
work_keys_str_mv | AT duongnguyenxuong heterogeneityofhipposignallingactivityindifferenthistopathologicsubtypesofrenalcellcarcinoma AT leminhkhang heterogeneityofhipposignallingactivityindifferenthistopathologicsubtypesofrenalcellcarcinoma AT kondotetsuo heterogeneityofhipposignallingactivityindifferenthistopathologicsubtypesofrenalcellcarcinoma AT mitsuitakahiko heterogeneityofhipposignallingactivityindifferenthistopathologicsubtypesofrenalcellcarcinoma |